Vulvar and Vaginal Atrophy: Physiology, Clinical Presentation, and Treatment Considerations

Clinical Obstetrics and Gynecology

Volumn 58, Issue 3, 2015, Pages 476-491

  Lev Sagie, Ahinoam ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

atrophy; low estrogen; vagina; vulva

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; LUBRICATING AGENT; PRASTERONE; PROMESTRIENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ALTERNATIVE MEDICINE; BREAST CANCER; BREAST TENDERNESS; CLINICAL FEATURE; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; ESTROGEN THERAPY; HUMAN; LABORATORY DIAGNOSIS; LOCAL THERAPY; LOW DRUG DOSE; PHYSIOLOGY; REVIEW; SEXUAL INTERCOURSE; SYMPTOM; VAGINA ATROPHY; VAGINA BLEEDING; VAGINA CANDIDIASIS; VULVA DISEASE; VULVAR ATROPHY; AGING; ATROPHY; FEMALE; INTRADERMAL DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; MENOPAUSE; PATHOLOGY; PATHOPHYSIOLOGY; PROCEDURES; VAGINA; VAGINAL DISEASES; VULVA; VULVAR DISEASES;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVAGINAL; AGING; ATROPHY; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LUBRICANTS; MENOPAUSE; VAGINA; VAGINAL DISEASES; VULVA; VULVAR DISEASES;

EID: 84938573571     PISSN: 00099201     EISSN: 15325520     Source Type: Journal    
DOI: 10.1097/GRF.0000000000000126     Document Type: Review

References (22)

1. Portman DJ, Gass MLS. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and The North American Menopause Society. Menopause. 2014;21:1063-1068.
2. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20:888-902. Available at: http://www.ncbi.nlm.nih.gov/pubmed/term=Management+of+symptomatic+ vulvo vaginal++nams.
3. Bachmann G, Santen RJ. Clinical manifestations and diagnosis of vaginal atrophy. In: BarbieriRL, ed. UpToDate,Waltham, MA: Waltham, Mass; 2014. Available at: http://www.uptodate.com/contents/clinical-manifestations-and-diagnosisof-vaginal-atrophy?source=related-link.Accessed November 20, 2014.
4. Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc. 2010;85:87-94.
5. Cotreau MM, Chennathukuzhi VM, Harris HA, et al. A study of 17beta-estradiol-regulated genes in the vagina of postmenopausal women with vaginal atrophy. Maturitas. 2007;58:366-376.
6. Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013; 5:437-447.
7. Dennerstein L, Dudley EC, Hopper JL, et al. A prospective population-based study of menopausal symptoms. Obstet Gynecol. 2000;96:351-358.
8. Johnston SL, Farrell SA, Bouchard C, et al. The detection and management of vaginal atrophy. J Obstet Gynaecol Can. 2004;26:503-515.
9. Bachmann G, Santen RJ. Treatment of vaginal atrophy. In: Barbieri RL, ed. UpToDate,Waltham, MA: Waltham, Mass; 2014. Available at: http://www.uptodate.com/contents/treatment-of-vaginalatrophy. Accessed November 20, 2014.
10. Sinha A, Ewies AAA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric. 2013;16:305-312.
11. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23:259-263.
12. Cardozo L, Bachmann G, McClish D, et al. Metaanalysis of estrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1998;92(4 pt 2): 722-727.
13. Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausalwomen. Cochrane Database Syst Rev. 2006;4:CD001500.
14. Fischer G, Bradford J. Vulvovaginal candidiasis in postmenopausal women: the role of hormone replacement therapy. J Low Genit Tract Dis. 2011;15:263-267.
15. Labrie F, Archer D, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause. 2009;16:897-906.
16. Panjari M, Davis SR. Vaginal DHEA to treat menopause related atrophy: a review of the evidence. Maturitas. 2011;70:22-25.
17. Moegele M, Buchholz S, Seitz S, et al. Vaginal estrogen therapy for patients with breast cancer. Geburtshilfe Frauenheilkd. 2013;73: 1017-1022.
18. Baumgart J, Nilsson K, Stavreus-Evers A, et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol. 2011;204:26e1-26e7.
19. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003;6:45-52.
20. Goetsch MF, Lim JY, Caughey AB. A solution for dyspareunia in breast cancer survivors: a randomized controlled study. Obstet Gynecol. 2014;123(suppl):1S.
21. Signorello LB, Harlow BL, Chekos AK, et al. Postpartum sexual functioning and its relationship to perineal trauma: a retrospective cohort study of primiparous women. Am J Obstet Gynecol. 2001;184:881-888.
22. Wisniewski PM, Wilkinson EJ. Postpartum vaginal atrophy. Am J Obstet Gynecol. 1991; 165(4 pt 2):1249-1254.